FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

- Advertisement -

Dr. Reddy’s Laboratories announced that it will be launching Lansoprazole delayed-release capsules (15 mg and 30 mg), a bioequivalent generic version of Prevacid®* Delayed-Release Capsules, in the US market. The Food & Drug Administration (FDA) approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules on October 15, 2010. Launch preparations are complete and shipments will commence shortly. Dr. Reddy’s Lansoprazole delayed-release capsules are available in bottles of 30 & 90 counts in 15mg and 90 and 500 counts in 30 mg.

EU Pharmaceutical Legislation to be Reformed After 2 Decades

Eli Lilly to Invest over $6bn on the New Huntsville Facility

Thermo Fisher to Expand Bioprocess Design Centers in Asia

Bora – Corealis Collaborate for Oral Solid Dose Development

Eli Lilly & IU Join Hands to Expand Clinical Trials Access

Future-proof vial filling – How flexibility Along the Line Defines Success

How Smart Digital Strategies are Leading the Way in Pharmaceutical Manufacturing

Rethinking Real-World Data Partnerships: How to Fill Gaps Without Starting Over

Energy efficiency in pure steam generation: How small adjustments can lead…

Pharmacovigilance Systems Gaining Higher Ground with AI

India Outpaces Global Average With 2026 Medical Trend at 11.5 Percent:…

Symbiosis Formally Presented with Prestigious King’s Award by Lord Lieutenant of…

STERILINE RETURNS TO CPHI & PMEC INDIA AND CELEBRATES THE HUNDREDTH…

Syntegon Reports Strong Q3 2025 Growth and Margin Expansion

API China – The Pharmaceutical Ingredients Exhibition Concludes

FDA approved Dr. Reddy’s ANDA for Lansoprazole delayed-release capsules

EU Pharmaceutical Legislation to be Reformed After 2 Decades

Eli Lilly to Invest over $6bn on the New Huntsville Facility

Thermo Fisher to Expand Bioprocess Design Centers in Asia

EU Pharmaceutical Legislation to be Reformed...

Eli Lilly to Invest over $6bn...

Thermo Fisher to Expand Bioprocess Design...

The Psychology Behind Overthinking and How...

Steps to Start a Career in...

How Psychology Shapes the Way We...

EU Pharmaceutical Legislation to be Reformed After 2 Decades

Eli Lilly to Invest over $6bn on the New Huntsville Facility

Thermo Fisher to Expand Bioprocess Design Centers in Asia

Bora – Corealis Collaborate for Oral Solid Dose Development

About us

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

EU Pharmaceutical Legislation to be Reformed After 2 Decades

Eli Lilly to Invest over $6bn on the New Huntsville Facility